Clinical Trials Logo

Pseudomonas Infections clinical trials

View clinical trials related to Pseudomonas Infections.

Filter by:

NCT ID: NCT01035853 Completed - Cystic Fibrosis Clinical Trials

Sino-nasal Inhalation of Colistin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization

Start date: December 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether the nasal inhalation of Colistin is effective to decrease the Pseudomonas aeruginosa bacterial count in the nasal lavage fluid.

NCT ID: NCT00910351 Completed - Clinical trials for Pseudomonas Infection

Cipro Inhaler for Cystic Fibrosis Children Ages 6-12

Start date: July 2009
Phase: Phase 1
Study type: Interventional

Ciprofloxacin PulmoSphere Inhalation Powder appears to be an effective and adequate antibiotic treatment for cystic fibrosis patients with P. aeruginosa colonisation. This planned study is the first study on the use of this new Ciprofloxacin PulmoSphere Inhalation Powder in the pediatric population of 6 to 12 years of age.

NCT ID: NCT00778388 Completed - Healthy Clinical Trials

Study Assessing Safety and Immunogenicity of IC43 Vaccination Against Pseudomonas Aeruginosa in Healthy Volunteers

Start date: September 2008
Phase: Phase 1
Study type: Interventional

The objective is to confirm the optimal dose of IC43 in regard to immunogenicity, safety and tolerability.

NCT ID: NCT00775138 Completed - Bronchiectasis Clinical Trials

Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.

Start date: June 24, 2008
Phase: Phase 2
Study type: Interventional

This is a study to determine the safety and tolerability of 28 days of daily dosing of two doses (280 mg and 560 mg) of Arikayce™ versus placebo in patients who have bronchiectasis and chronic infection due to Pseudomonas infection.

NCT ID: NCT00774072 Completed - Cystic Fibrosis Clinical Trials

Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization

Start date: October 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether the nasal inhalation of Gernebcin® is effective to decrease the Pseudomonas aeruginosa bacterial count in the nasal lavage fluid.

NCT ID: NCT00712166 Completed - Cystic Fibrosis Clinical Trials

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa

AIR-CF4
Start date: May 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the safety and efficacy of a 28-day course of aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF), mild lung disease (forced expiratory volume in 1 second [FEV1] >75% predicted, and Pseudomonas aeruginosa (PA) infection.

NCT ID: NCT00691587 Completed - Clinical trials for Ventilator Associated Pneumonia

Pilot Trial of KB001 in Mechanically-Ventilated Patients Colonized With Pseudomonas Aeruginosa

Start date: April 2008
Phase: Phase 1/Phase 2
Study type: Interventional

Pseudomonas aeruginosa is an opportunistic pathogen that rarely causes disease in healthy people, but is a significant problem for critically ill or immunocompromised individuals. Experts estimate that there are greater than 100,000 patients in the United States, Europe and Japan where Pseudomonas pneumonia occurs. Patients with Pseudomonas pneumonia currently represent only about 20% of the patients in the hospital who get Pseudomonas infections.

NCT ID: NCT00638365 Completed - Cystic Fibrosis Clinical Trials

Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa

Start date: March 2008
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the safety and tolerability of a single dose of KB001 in Cystic Fibrosis patients infected with Pseudomonas aeruginosa (Pa)

NCT ID: NCT00634192 Completed - Clinical trials for Pseudomonas Infections

Pharmacokinetic Evaluation of an 8 -Week Treatment With Inhaled Tobramycin

Start date: February 2008
Phase: Phase 3
Study type: Interventional

This study is designed to provide data about the pharmacokinetics (PK), safety and tolerability of two continuous treatment regimes of tobramycin nebulized solution delivered via a 'soft mist' nebulizer in Cystic Fibrosis (CF) subjects. Each treatment period will last 8 weeks. Additionally the PK of patients with a normal forced expiratory flow in 1 second (FEV1) (FEV1≥80% predicted) will be compared to patients with an abnormal FEV1 (FEV1<80% predicted).

NCT ID: NCT00633191 Completed - Cystic Fibrosis Clinical Trials

Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis

PseudIgY
Start date: November 2003
Phase: Phase 1/Phase 2
Study type: Interventional

Hypothesis: Daily gargling with specific avian antibodies against Pseudomonas aeruginosa will prevent infections with this bacteria in patients with Cystic fibrosis (CF).